Navigating ALK Inhibitor Toxicities

Raludotatug deruxtecan (R-DXd) earned FDA breakthrough designation for CDH6-expressing platinum-resistant ovarian cancers after bevacizumab (Avastin; Genentech) treatment.

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

The evolving treatment landscape for unfit patients with newly diagnosed acute myeloid leukemia (AML) centers on venetoclax combination and personalized strategies.

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Patients with acute myeloid leukemia (AML) in remission for over 3 years experience survival rates comparable with a matched cohort from the general population.

Female patients with chronic spontaneous urticaria (CSU) face greater disease severity and burdens, particularly in midlife, a study found.